GLP-1 receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-20. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
=== Heavy metals === Heavy metals are toxic for living organisms. High soil concentrations of heavy metals such as zinc, copper, cadmium, lead, nickel, and chromium affect basic metabolic processes and can lead to cell damage and death. Some ectomycorrhizal fungi are tolerant to heavy metals, with many species having the ability to colonize contaminated soils. There are also cases of populations locally adapted to tolerate harsh chemical environments. Fungi exhibit detoxification mechanisms to reduce heavy metal concentrations in their cells. These mechanisms include reducing heavy metal uptake, sequestering and storing heavy metals within the cell, and excretion. Heavy metal uptake can be reduced by sorption and metabolic inactivation at the cell wall and apoplast level. Ectomycorrhizal fungi also have the ability to bind considerable amounts of heavy metals. Once inside the cell, heavy metals can be immobilized in organo-metal complexes, made soluble, transformed into metallothioneins, involved in metal sequestration and/or stored in vacuoles in chemically inactive forms. Antioxidant detoxification systems may also be in place, reducing the production of free radicals and protecting the fungal cell. Fungi can export metals from the cytoplasm to the apoplast, a mechanism that also occurs in plants. Ectomycorrhizal fungi can also concentrate heavy metals in their fruiting bodies. Genetic differences between populations growing in toxic versus non-toxic habitats have rarely been reported, indicating that metal tolerance is widespread.
As in the 2023 election, the electoral system followed that of the 2021 amendment of the 2017 constitution. The 500 members of the House of Representatives were elected by parallel voting. 400 seats were elected from single-member constituencies by first-past-the-post voting and 100 seats by proportional representation. Voters cast separate ballots for the two sets of seats. The 100 party-list seats were distributed under the "100 divisor" formula, restored in 2022 after parliament failed to finalise a rival draft within its 180-day deadline. The national party-list vote is divided by 100 to give a quota; each party takes one seat for every whole quota it has won, and the seats still unfilled go to the parties with the largest fractional remainders. List seats are awarded on top of constituency seats rather than in compensation for them, so a party that sweeps the constituencies keeps its full proportional entitlement as well. Writing shortly before the system was first used, Napon Jatusripitak of the ISEAS–Yusof Ishak Institute observed that cutting the number of list seats from 150 to 100 raised the share of the vote needed to win one and allowed larger parties to take a higher proportion of seats than of votes. At the 2026 election the 35,030,579 valid party-list votes produced a quota of 350,306.
The ADGRG1 protein couples to Gαq/11 protein upon association with the tetraspanins CD9 and CD81. Forced ADGRG1 expression activates NF-kB, PAI-1, and TCF transcriptional response elements. The splicing of ADGRG1 induces tumorigenic responses as a result of activating the transcription of genes, such as COX2, iNOS, and VEGF85. ADGRG1 couples to the Gα12/13 protein and activates RhoA and mammalian target of rapamycin (mTOR) pathway upon ligand binding. Lack of the N-terminal fragment (NTF) of ADGRG1 causes stronger RhoA signaling and β-arrestin accumulation, leading to extensive ubiquitination of the C-terminal fragment (CTF). Finally, ADGRG1 suppresses PKCα activation to regulate angiogenesis.
=== Interpretation === A key concept in interpreting radiocarbon dates is archaeological association: what is the true relationship between two or more objects at an archaeological site? It frequently happens that a sample for radiocarbon dating can be taken directly from the object of interest, but there are also many cases where this is not possible. Metal grave goods, for example, cannot be radiocarbon dated, but they may be found in a grave with a coffin, charcoal, or other material which can be assumed to have been deposited at the same time. In these cases, a date for the coffin or charcoal is indicative of the date of deposition of the grave goods, because of the direct functional relationship between the two. There are also cases where there is no functional relationship, but the association is reasonably strong: for example, a layer of charcoal in a rubbish pit provides a date which has a relationship to the rubbish pit. Contamination is of particular concern when dating very old material obtained from archaeological excavations and great care is needed in the specimen selection and preparation. In 2014, Thomas Higham and co-workers suggested that many of the dates published for Neanderthal artifacts are too recent because of contamination by "young carbon". As a tree grows, only the outermost tree ring exchanges carbon with its environment, so the age measured for a wood sample depends on where the sample is taken from. This means that radiocarbon dates on wood samples can be older than the date at which the tree was felled.
Lithium-ion batteries can be a safety hazard since they contain a flammable electrolyte and may become pressurized if they become damaged. A battery cell charged too quickly could cause a short circuit, leading to overheating, explosions, and fires. A Li-ion battery fire can be started due to
Sources: en.wikipedia.org
Sfinxul is a natural rock formation in the Bucegi Natural Park which is in the Bucegi Mountains of Romania. This rock formation is named for its resemblance to the Sphinx of Giza, and is located at an altitude of 2,216 metres (7,270 feet) within the Babele complex of rock formations.
=== Background === Before bitcoin, several digital cash technologies were released, starting with David Chaum's ecash in the 1980s. The idea that solutions to computational puzzles could have some value was first proposed by cryptographers Cynthia Dwork and Moni Naor in 1992. The concept was independently rediscovered by Adam Back who developed Hashcash, a proof-of-work scheme for spam control in 1997. The first proposals for distributed digital scarcity-based cryptocurrencies came from cypherpunks Wei Dai (b-money) and Nick Szabo (bit gold) in 1998. In 2004, Hal Finney developed the first currency based on reusable proof of work. These various attempts were not successful: Chaum's concept required centralized control and no banks wanted to sign on, Hashcash had no protection against double-spending, while b-money and bit gold were not resistant to Sybil attacks.
==== Officer of the Order of the British Empire (OBE) ==== Military Division Royal Navy Commander Peter David Ambrose. Commander Charles Anthony Johnstone-Burt. Major Stephen John Duyland Bush, Royal Marines. Commander Michael John Channon. Commander Brian Paul Boxall-Hunt. Commander George McAleese. Commander Peter John Linstead-Smith. Army Lieutenant Colonel Peter John Barrett (482686), Adjutant General's Corps (SPS). Lieutenant Colonel Brian McDonnell (509404), The Royal Anglian Regiment. Lieutenant Colonel George McGarr (508552), The Royal Logistic Corps. Lieutenant Colonel Brian Nutt (489575), Corps of Royal Electrical and Mechanical Engineers. Lieutenant Colonel Keith Henry Neville Prentice (488202), Royal Regiment of Artillery. Acting Colonel John David Reason (467319), Devonshire Army Cadet Force, Territorial Army. Lieutenant Colonel John David Sainsbury, , (453727), Royal Regiment of Artillery (Volunteers), Territorial Army. Lieutenant Colonel John Alexander Broome Salmon (486736), The Princess of Wales's Royal Regiment. Lieutenant Colonel John Alexander Thomson (496402) The Cheshire Regiment (Volunteers), Territorial Army. Lieutenant Colonel Philip Roy West (485857), Royal Regiment of Artillery. Royal Air Force Wing Commander Michael Carl Barter (8026633). Wing Commander Walter Simon Erskine Crum (0608265). Wing Commander Nigel Kenneth Gillingham (5203514). Wing Commander Malcolm Kenneth Hinder (0207878), Royal Air Force Volunteer Reserve (Training). Wing Commander Michael John Jones (0685361). Wing Commander Brian David Longman (0609376).
=== Skin and hair conditions === Androgens such as testosterone and DHT play a critical role in the pathogenesis of a number of dermatological conditions including oily skin, acne, seborrhea, hirsutism (excessive facial/body hair growth in women), and male pattern hair loss (androgenic alopecia). In demonstration of this, women with complete androgen insensitivity syndrome do not produce sebum or develop acne and have little to no body, pubic, or axillary hair. Moreover, men with congenital 5α-reductase type II deficiency, 5α-reductase being an enzyme that greatly potentiates the androgenic effects of testosterone in the skin, have little to no acne, scanty facial hair, reduced body hair, and reportedly no incidence of male-pattern hair loss. Conversely, hyperandrogenism in women, for instance due to polycystic ovary syndrome or congenital adrenal hyperplasia, is commonly associated with acne and hirsutism, as well as virilization (masculinization) in general. In accordance with the preceding, antiandrogens are highly effective in the treatment of the aforementioned androgen-dependent skin and hair conditions. Because of the antiandrogenic activity of spironolactone, it can be quite effective in treating acne in women. In addition, spironolactone reduces oil that is naturally produced in the skin, so can be used to treat oily skin. Though not the primary intended purpose of the medication, the ability of spironolactone to be helpful with problematic skin and acne conditions was discovered to be one of the beneficial side effects and has been quite successful.
Sources: en.wikipedia.org
Andress, Jason. Winterfeld, Steve. (2011). Cyber Warfare: Techniques, Tactics and Tools for Security Practitioners. Syngress. ISBN 1-59749-637-5 Bodmer, Kilger, Carpenter, & Jones (2012). Reverse Deception: Organized Cyber Threat Counter-Exploitation. New York: McGraw-Hill Osborne Media. ISBN 0-07-177249-9, "ISBN 978-0-07-177249-5" Brenner, S. (2009). Cyber Threats: The Emerging Fault Lines of the Nation State. Oxford University Press. ISBN 0-19-538501-2 Carr, Jeffrey. (2010). Inside Cyber Warfare: Mapping the Cyber Underworld. O'Reilly. ISBN 978-0-596-80215-8 Conti, Gregory. Raymond, David. (2017). On Cyber: Towards an Operational Art for Cyber Conflict. Kopidion Press. ISBN 978-0-692-91156-3 Cordesman, Anthony H.; Cordesman, Justin G. (2002). Cyber-threats, Information Warfare, and Critical Infrastructure Protection: Defending the U.S. Homeland. Greenwood Publishing Group. ISBN 978-0-275-97423-7. Costigan, Sean S.; Perry, Jake (2012). Cyberspaces and global affairs. Farnham, Surrey: Ashgate. ISBN 978-1-4094-2754-4. Fritsch, Lothar & Fischer-Hübner, Simone (2019). Implications of Privacy & Security Research for the Upcoming Battlefield of Things. Journal of Information Warfare, 17(4), 72–87. Gaycken, Sandro. (2012). Cyberwar – Das Wettrüsten hat längst begonnen. Goldmann/Randomhouse. ISBN 978-3-442-15710-5 Geers, Kenneth. (2011). Strategic Cyber Security. NATO Cyber Centre.
=== Bu === John Buchanan (1917–2007). American biochemist at MIT, best known for his research on the biosynthesis of purines. Member Natl. Acad. Sci. USA. Eduard Buchner (1860–1917). German chemist and physiologist at LMU Munich, who overthrew the doctrine of vitalism by showing that cell-free yeast extract could catalyse fermentation, a discovery described by Arthur Kornberg as the beginning of biochemistry. 1907 Nobel Prize in Chemistry. Dean Burk (1904–1988). American biochemist at the Fixed Nitrogen Research Laboratory, co-discoverer of biotin. He is credited (with Hans Lineweaver) with introducing the double-reciprocal plot in kinetics. He became a vociferous opponent of water fluoridation. Robert H. Burris (1914–2010). American biochemist at the University of Wisconsin–Madison, expert on nitrogen fixation. Member Natl. Acad. Sci. USA. Stephen Busby (DPhil 1975) FRS, biochemist at the University of Birmingham. Carlos Bustamante (b. 1951). Peruvian-American biophysicist at UC Berkeley. Known for single-molecule studies, including the use of optical tweezers for measuring the forces that maintain biological structures. Member Natl. Acad. Sci. USA.
=== Energy intensity === The langley (symbol Ly) is used to measure solar radiation or insolation. It is equal to one thermochemical calorie per square centimetre (4.184×104 J/m2 or ≈3.684 BTU/sq ft) and was named after Samuel Pierpont Langley. Its symbol should not be confused with that for the light-year, ly.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.